KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic diseaseKT-621 ...

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...

Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...

Repurposing of a drug designed for pain relief can quickly and reversibly slow biochemical and metabolic activities in cells and organs and could facilitate organ transplantation and prevent tissue ...

FDA approved blinded, multi-centric Phase-3 trial (NCT06489028) to investigate the safety and efficacy of allo-APZ2-CVU in ...

The skincare hot list for those of us who won’t do needles but will slather our faces with whatever truly works.

Axial Spondyloarthritis (axSpA) is a form of arthritis that mainly causes discomfort and inflammation in the spine and ...

Mechanistically, interleukin (IL)-6 signals via Jak to activate Yes-associated protein (Yap), which forms a complex with Snail to drive the invasiveness of SF, and selective targeting of Yap in ...

Interleukin-6 levels were associated with an increased risk for obesity-related cancer among individuals with newly diagnosed type 2 diabetes.

The sale to Oyo, a travel business, will include the Studio 6 motel brand, which caters to customers seeking extended stays.

After comparing many NMN supplements, here are the top three. These products should offer dynamic longevity support with ...